Market Overview

UPDATE: Stifel Nicolaus Initiates Oncolytics Ciotech at Buy with $6 PT on Reolysin Cancer Focus

Share:
Related ONCY
Morning Market Gainers
The FDA Just Gave Oncolytics Biotech A Big Bump
60 minutes piece highlights promise of cancer-killing viruses (Seeking Alpha)

Stifel Nicolaus initiated its coverage on Oncolytics Ciotech (NASDAQ: ONCY) with a Buy rating and a price target of $6 a share.

Stifel Nicolaus commented, "We view ONCY's sole clinical candidate Reolysin as a compelling potential treatment for ~60% of cancers. Reolysin is a specific strain of a naturally occurring virus that only replicates in cancer cells with an activated Ras signaling pathway, a key metabolic pathway in cell metabolism that is mutated in over 60% of all carcinomas. Reolysin has demonstrated compelling efficacy in numerous oncology indications and as a live virus Reolysin's main side effect is "viral syndrome", not the typical side effects of chemotherapy."

Oncolytics Ciotech closed at $2.76 on Wednesday.

Latest Ratings for ONCY

DateFirmActionFromTo
Sep 2013NeedhamInitiates Coverage onBuy
Mar 2013Piper JaffrayInitiates Coverage onOverweight
Dec 2012Bloom Burton & Co.DowngradesBuyHold

View More Analyst Ratings for ONCY
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ONCY)

Around the Web, We're Loving...